|Bid||0.0000 x 800|
|Ask||0.0000 x 3000|
|Day's Range||4.1200 - 4.2490|
|52 Week Range||0.6620 - 4.6800|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 09, 2021 - Aug. 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Jun 18, 2021--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grant of a non-statutory stock option to one new employee in connection with the employee’s commencement of employment with Sesen Bio. The addition of this new team member represents a continuation of the buildout of the Sesen Bio team in support of its transformation into a commercial-stage company a
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Sesen Bio...